Natixis Advisors LLC Buys 13,616 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Natixis Advisors LLC boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 29.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,253 shares of the biopharmaceutical company’s stock after purchasing an additional 13,616 shares during the period. Natixis Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after acquiring an additional 151,495 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after purchasing an additional 79,182 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in Catalyst Pharmaceuticals by 74.3% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after buying an additional 312,000 shares during the period. Bank of New York Mellon Corp increased its holdings in Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company’s stock valued at $15,100,000 after buying an additional 9,194 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in Catalyst Pharmaceuticals by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 600,488 shares of the biopharmaceutical company’s stock worth $12,532,000 after acquiring an additional 24,535 shares during the period. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 0.1 %

Shares of CPRX stock opened at $25.72 on Wednesday. The stock’s 50-day moving average price is $22.53 and its 200-day moving average price is $21.72. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $26.16. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of 21.80, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CPRX has been the subject of several analyst reports. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens reaffirmed an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.